NCI

The study solidified how doctors should interpret and act upon an intermediate result from the breast cancer risk test in how to treat early-stage patients.

The partners will use NanoString's PanCancer panel in NCI-sponsored trials to characterize immune activity and develop potentially predictive gene signatures.

Researchers found that some molecularly defined subsets of patients responded to targeted drugs while others didn't.

The third set of papers out this week from The Cancer Genome Atlas touches on ways to cluster tumors, oncogenic processes that contribute to oncogenesis, and more.

Researchers associated with the Cancer Genome Atlas (TCGA) Research Network will publish more than 25 papers this week to discuss findings from the initiative.

St. Louis-based Cofactor will use the National Cancer Institute's clinical specimens in order to validate its Paragon assay platform.

This Week in PNAS

In PNAS this week: half-a-dozen Aspergillus sequenced, genetic similarities between friends and classmates, and more.

This Week in PNAS

In PNAS this week: epigenetic differences in wild, farmed Coho salmon; RNA editing in immune cells; and more.

All Together Now

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

This Week in PNAS

In PNAS this week: genes selected for in potato domestication, method sequencing and haplotyping analysis on single cells, and more.

Pages

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.